Human Albumin Csl Behring (Human Plasma Protein)

Human Albumin Csl Behring is a sterile solution for injection that contains human plasma protein (human albumin) as the active ingredient; the specific strength is not disclosed. Marketed in the European Union, this prescription‑only product is used to restore plasma volume and protein levels in clinical settings. It is administered intravenously under medical supervision. It is supplied in single‑use vials and stored at controlled temperature to maintain protein integrity.

Human Albumin Csl Behring is indicated for clinical situations that require rapid plasma volume expansion or correction of low albumin levels.

- Treatment of hypovolemia associated with trauma, surgery, or dehydration. - Management of shock and severe burns where fluid loss is extensive. - Replacement of plasma proteins during massive transfusion or plasma exchange. - Support of patients with hypoalbuminemia due to liver disease, nephrotic syndrome, or malnutrition. - Adjunct therapy during cardiac surgery or organ transplantation to maintain oncotic pressure.

Adverse reactions to Human Albumin Csl Behring are generally infrequent but may occur following intravenous administration.

Common: - Mild fever or chills during infusion. - Transient headache or dizziness. - Nausea or mild gastrointestinal discomfort. - Localized erythema or swelling at the injection site.

Serious: - Anaphylactic or severe allergic reactions, including urticaria and bronchospasm. - Volume overload leading to pulmonary edema, especially in patients with cardiac dysfunction. - Hemolysis or renal impairment in susceptible individuals. - Transmission of infectious agents, although risk is minimized by manufacturing controls.

Healthcare professionals should evaluate patient history and clinical status before administering Human Albumin Csl Behring.

- Assess for known hypersensitivity to albumin or any component of the formulation. - Evaluate cardiac, renal, and hepatic function to avoid volume overload. - Use caution in patients with active bleeding or coagulopathy, as albumin may affect clotting factors. - Monitor vital signs and fluid balance during and after infusion. - Adjust dose or infusion rate in elderly or critically ill patients. - Avoid use in patients with severe hypervolemia or uncontrolled hypertension.

Human Albumin Csl Behring may interact with other therapies that influence fluid balance, coagulation, or immune response.

Avoid: - Concurrent administration of high‑dose diuretics without careful monitoring, which can exacerbate hypovolemia. - Simultaneous use of other plasma expanders or colloids that may increase the risk of volume overload. - Blood products containing incompatible antibodies that could trigger hemolytic reactions.

Use with caution: - Vasopressors or inotropic agents, as rapid volume changes may alter hemodynamic response. - Anticoagulants (e.g., heparin, warfarin) because albumin can affect plasma protein binding. - Immunosuppressive drugs, given the potential for altered immune modulation. - Renal replacement therapies, where fluid shifts need close observation.